CVE-2026-50034

HIGHCVSS 7.1/10EPSS 0.14%

Last modified

CVE-2026-50034 is a high-severity vulnerability rated 7.1/10 on the CVSS scale. An attacker within BLE communication range can passively intercept wireless traffic and obtain sensitive health-related information, including glucose measurement values.. EPSS estimates a 0.14% chance of exploitation in the next 30 days.

Description

An attacker within BLE communication range can passively intercept wireless traffic and obtain sensitive health-related information, including glucose measurement values.

Metrics

Weakness Enumeration

Affected Software

Source: CNA advisory (CVE.org). NVD analysis pending.

VendorProductVersions
Apollo PharmacyBlood Glucose Monitoring System (Model No. APG-01 BT)0x0110_v1.1.0

References

Timeline

Published
Last Modified
Status
Awaiting Analysis

Frequently Asked Questions

What is CVE-2026-50034?
An attacker within BLE communication range can passively intercept wireless traffic and obtain sensitive health-related information, including glucose measurement values.
How severe is CVE-2026-50034?
CVE-2026-50034 has a CVSS score of 7.1/10 (HIGH severity). The EPSS model estimates a 0.14% probability of exploitation in the next 30 days.
How do I fix CVE-2026-50034?
Check the vendor references and advisories linked above for patched versions and mitigation guidance. You can also run a Strix scan to test if your systems are affected.

How Strix Helps

Related CVEs from 2026

Are you affected by CVE-2026-50034?

Run a free Strix scan to check your systems for this vulnerability.

Scan your code now

Source: NVD / NIST